Trinity Co-Founder and President John Corcoran discussed Trinity’s 2016 Drug Index and 20th anniversary on the Bloomberg Baystate Business Hour with Anne Mostue and Tom Moroney. Listen to the full program here: http://bloom.bg/2gzr59P. John’s segment begins at 7 minutes, 20 seconds.
The Trinity 2016 Drug Index argues that Biogen’s blockbuster multiple sclerosis treatment Tecfidera was the biggest commercial success of roughly two dozen novel drugs approved in 2013, but other biotech firms in the Bay State didn’t fare quite as well. In the study released on Wednesday, Trinity examined 22 novel drugs — those that represented a significant step forward in innovation — approved by the FDA in 2013. Trinity then ranked them based on commercial success, therapeutic success, and the cost and duration of research and development efforts. Not enough data was available to assess five other novel drugs approved in 2013. See the full article here: http://bit.ly/2fAhSBa
Trinity Partners announced today the findings of its first annual ‘Trinity Drug Index,’ a comprehensive research-based report which assessed 22 novel drugs approved by the FDA in 2013. The Index rates drug performance as measured by a retrospective look at commercial success relative to therapeutic value and R&D complexity, assigning each drug a score in those three areas as well as an overall composite score.
Top findings of this year’s Trinity Drug Index include:
- Sovaldi, which treats Hepatitis C, received the highest ranking with an overall score of 4.4 out of 5
- Most of the top performers were specialty drugs
- Drugs for primary care markets such as COPD and diabetes tend to show weaker differentiation and limited commercial performance, exacerbated by significant R&D expense
- Commercial underperformance given significant therapeutic value is rare, and could be due to a rapidly changing competitive environment
- Well-executed business strategy may boost commercial performance of drugs that are not vastly superior therapeutically
- Moving forward, it will be more critical than ever to demonstrate a product’s value vis-à-vis existing competition
If you would like to read the full whitepaper, it is available for free on the Trinity Partners website HERE.
New science drives biopharma interest in neurological conditions.
Read the article HERE
If Roche’s Ocrevus is approved, the already competitive MS market will gain another player.
Read the article HERE
Executives from Trinity Partners and Sage Therapeutics conducted a study to provide an estimate of the annual number of super-refractory status epilepticus (SRSE) cases in the US and to evaluate utilization of hospital resources by these patients, using hospital chargemaser data. The study suggests that SRSE is associated with high mortality and morbidity, and significant use of healthcare resources. Read the full report here: http://www.tandfonline.com/doi/full/10.1080/13696998.2016.1223680?scroll=top&needAccess=true
Partner Herman Sanchez commented on the changing specialty sales and marketing landscape in the October issue of PharmaVOICE. In the story, Herman remarked that companies now routinely involve health economic functions early in the decision-making process and in the development of the core value proposition. Said Herman, “Developing a value story for the product is now absolutely essential to the success of the product.”
In the September issue of PharmaVOICE, Senior Partner Leslie Sandberg Orne comments on the challenges behind marketing CNS therapies. In the story, Leslie addresses the top factors driving CNS prescribing habits, as well as the reimbursement process for CNS therapies and how the marketplace may evolve in the next 5-10 years.
Read more here: http://bit.ly/2bxjdUh
Partner Ryan Million discusses ongoing clinical and financial trends related to the oncology market, and their impact on both drug manufacturers and payers: http://bit.ly/1YnOV8F